Article
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Nov 2008
Wu I-Chin, Shiffman Mitchell L, Tong Myron J, Marcellin Patrick, Mondou Elsa, Frederick David, Snow-Lampart Andrea, Sorbel Jeff, Rousseau Franck, Chang Ting-Tsung
Abstract excerpt
BACKGROUND: This study evaluated the persistence of hepatitis B e antigen (HBeAg) seroconversion (which is considered to be an important therapeutic end point) after adefovir dipivoxil treatment. METHODS: Forty-five patients who experienced confirmed HBeAg seroconversion and had a serum hepatitis B virus DNA level < 10(5) copies/mL while receiving 10 mg of adefovir dipivoxil in a prior study were enrolled in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.